People infected with Kent coronavirus variant are MORE likely to get symptoms, ONS report reveals


People infected with the Kent coronavirus variant are more likely to get symptoms than those who have caught older strains but are less likely to lose their smell and taste, according to the Office for National Statistics. 

Data from the ONS revealed today that 53 per cent of people in England who tested positive with the variant reported Covid-19 symptoms such as cough, fatigue and fever, compared to 48 per cent of people with other variants. 

The number-crunching body found that the largest differences in reported symptoms between the new variant and older stains were cough, sore throat, fatigue and muscle ache myalgia which is caused by a viral infection. 

All symptoms were equally or more likely among people with the Kent variant except for a loss of taste and smell, which is considered to be one of the tell-tale signs of the virus. 

The ONS report also found that there was no significant difference in people experiencing shortness of breath, nausea vomiting or headaches between people who had tested positive with the mutation or novel strain.  

Figures showed that 19 per cent of those who tested positive with the UK variant had a loss of smell and taste in comparison to other strains, among which it was 22 per cent.

The Government last week revealed that scientists think the Kent variant may be more deadlier than the previous dominant version of the virus, and it is already known to be more infectious by around 30 to 70 per cent.

The Kent strain now makes up around 60 per cent of all cases in England, according to separate ONS testing figures.

The Prime Minister told a Downing Street press conference last week: ‘In addition to spreading more quickly, it also now appears that there is some evidence that the new variant, the variant that was first identified in London and the South East, may be associated with a higher degree of mortality.’

In Figure 3, which analysed the percentage of people with symptoms by variant, experts found that ‘loss of taste and loss off smell were significantly less common in new variant compatible positives but added: ‘There is no evidence of difference in the gastrointestinal symptoms, shortness of breath or headaches.’  

Figures showed that 35 per cent who tested positive with the new variant experienced the symptom of a new, continuous cough in comparison with 28 per cent of people who were infected with older strains. 

Meanwhile 21 per cent with the Kent variant suffered from a sore throat while only 19 per cent of people experienced this symptom if they tested positive with older strains. 

Muscle ache myalgia, which can cause related symptoms such as tenderness and swelling, was reported by a quarter of people with the new variant in comparison with 22 per cent of those with older strains of the virus. 

The study also looked at the percentage of people who had tested positive for the virus in non-patient facing jobs in comparison to patient-facing roles such as nurses, surgeons, and paramedics.    

‘In recent weeks, there is evidence that the percentage testing positive has decreased in non-patient facing job roles but increased amongst those in patient-facing roles,’ the ONS report stated.  

The ONS reported that in the week ending January 9, the percentage of people who had tested positive for Covid-19 increased in those aged under 35 and over 35 in patient-facing roles. 

Figures showed that 3.6 per cent of people under the age of 35 in patient-facing roles tested positive for Covid-19 in the week ending January 9 compared with 3.4 per cent on January 1.  

Similarly the data also revealed that 3 per cent of people in patient-facing roles aged 35 and over tested positive for Covid-19 in the week ending January 9 compared with 2.7 per cent on January 1. 

Members of the New and Emerging Respiratory Virus Threats Advisory Group (Nervtag), a subcommittee of SAGE, compiled 10 different studies looking into the lethality of the new strain.

Eight found the variant was more deadly than previous strains, which led to the group concluding there was a ‘realistic possibility’.

But the findings from the studies varied wildly and had wide confidence intervals, which led to accusations that No10 was premature in announcing the development.

Chief Scientific adviser Sir Patrick even admitted during the press conference evidence the strain is more deadly is still ‘weak’.

Responding to those criticisms, Professor Edmunds said on Monday: ‘I think it’s pretty solid [the evidence] and if we had not said something about it, you’d be criticising the Government for not saying something about it and sweeping it under the carpet.’

Asked about what Kent strain’s increased deadliness means for lockdown, Professor Graham Medley, another SAGE member, said the new analysis was ‘concerning’ but doesn’t mean we need to do anything hugely different.

‘The situation is we’ve got about 100,000 infections a day and that is very serious. Additional mortality from new variant is concerning but it doesn’t change the effect of 100,000 [cases] ,that’s the main cause of the deaths.

‘If we want to reduce number of deaths we have to reduce incidence. Reduction of cases is the critical thing.’

What do we know about the Kent variant? 

Name: B.1.1.7, formerly VUI-202012/01

Where did it come from? The variant was first found in Kent and can be traced back to September 2020. Scientists noticed that it was spreading in November  and it was revealed to the public in December.

What makes it new? The variant, which is a version of the SARS-CoV-2 coronavirus that causes Covid-19, has a series of mutations that change the shape of the spike protein on its outside. The main one is known as N501Y. This appears to make it better able to stick to the cells inside the body and makes it more likely to cause infection and faster to spread.

How did that happen? Viruses, particularly ones spreading so fast and in such huge numbers, mutate all the time. To reproduce they basically force living cells to copy and paste the viral genetic code, and this can contain errors that lead to slightly different versions of the virus. Often these mutations make no difference but, if they make the virus stronger, they can stick around for further generations and become the norm. 

What can we do about it? Nothing much. People who catch the virus won’t know which type they have, and it will still cause the same symptoms and illness. Officials can try to contain it by locking down the areas where it is most prevalent, but if it is stronger than other versions of the virus it will eventually spread everywhere and become dominant as long as people continue to travel.  

Will our vaccines still work? Yes, it’s very likely they will. Scientists on SAGE are fairly sure the mutations the Kent variant carries do not significantly affect how well the immune system can handle it. People who have a vaccine modelled on an older version of the virus, or who have been infected with Covid-19 before, are likely to be immune to it. This is because the main mutations are only on one part of the spike protein, whereas the immune system is able to target various other parts of the virus. 

Read more at DailyMail.co.uk